Recovery trial for COVID-19Date: 21 May 2020 Tags: Miscellaneous
A recovery trial aims to study the effectiveness of four different drugs and anti-inflammatory drug tocilizumab for those with worsening clinical symptoms.
With a range of approved drugs now being tested on COVID-19 patients, there is no clarity on which one will turn out to be more effective in treatment compared with the standard of hospital care that all patients receive.
The recovery trial, coordinated by the Nuffield Department of Population Health at University of Oxford, will randomise patients to receive either standard of care or one of the four approved drugs.
The drugs being tested are HIV drugs Lopinavir-Ritonavir, anti-inflammatory corticosteroid (dexamethasone), anti-malaria drug hydroxychloroquine and antibiotic azithromycin.
Patients enrolled in the trial and have progressive COVID-19 with clinical evidence of hypoxia and inflammatory state may undergo a second randomisation to receive either tocilizumab (which blocks the inflammatory protein called IL-6) or no additional treatment.
The trial hopes to recruit 12,000 patients in all and will receive one of the four drugs or the standard of care for 10 days or till the date of hospital discharge and a second randomisation to receive tocilizumab or no treatment.
The secondary outcomes to be evaluated were reduction in hospital stay, number of patients who needed ventilation and the number of days it was required, and the number of patients who needed renal replacement therapy.